| 1.49 -0.09 (-5.7%) | 12-26 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 2.14 | 1-year : | 2.4 |
| Resists | First : | 1.83 | Second : | 2.05 |
| Pivot price | 1.75 |
|||
| Supports | First : | 1.48 | Second : | 1.23 |
| MAs | MA(5) : | 1.57 |
MA(20) : | 1.77 |
| MA(100) : | 4.48 |
MA(250) : | 0 | |
| MACD | MACD : | -0.2 |
Signal : | -0.3  |
| %K %D | K(14,3) : | 13.2 |
D(3) : | 15.9 |
| RSI | RSI(14): 32.4 |
|||
| 52-week | High : | 28.6 | Low : | 1.48 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ ARTL ] has closed above bottom band by 3.3%. Bollinger Bands are 80.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 65 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.55 - 1.56 | 1.56 - 1.57 |
| Low: | 1.46 - 1.48 | 1.48 - 1.49 |
| Close: | 1.47 - 1.49 | 1.49 - 1.51 |
Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing treatments to modulate the endocannabinoid system. Its product candidate pipeline includes ART27.13, a synthetic G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment of inflammatory bowel disease and post-traumatic stress disorder (PTSD); and ART26.12, a fatty acid binding protein 5 inhibitor for prostate and breast cancer treatment, as well as for treating PTSD. Artelo Biosciences, Inc. has research collaboration with Trinity College Dublin to investigate ART27.13 for the treatment of cancer cachexia. The company was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California.
Tue, 23 Dec 2025
Artelo Bioscience Commends Presidential Executive Order - GlobeNewswire
Mon, 01 Dec 2025
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
Wed, 15 Oct 2025
Artelo Biosciences reports positive data from two clinical programs - Investing.com
Mon, 29 Sep 2025
Artelo Biosciences, Inc. Announces Underwritten Public Offering of Common Stock and Pre-Funded Warrants - Quiver Quantitative
Fri, 05 Sep 2025
Artelo Biosciences Closes $3 Million Public Offering of Common Stock and Pre-Funded Warrants - Quiver Quantitative
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 2 (M) |
| Shares Float | 2 (M) |
| Held by Insiders | 0.4 (%) |
| Held by Institutions | 1.6 (%) |
| Shares Short | 102 (K) |
| Shares Short P.Month | 22 (K) |
| EPS | -19.5 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.41 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -136.3 % |
| Return on Equity (ttm) | -436.2 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -8 (M) |
| Levered Free Cash Flow | -3 (M) |
| PE Ratio | -0.08 |
| PEG Ratio | 0 |
| Price to Book value | -3.64 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.37 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|